Welcome to our dedicated page for HUMANA SEC filings (Ticker: HUM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Humana Inc. filings document formal disclosures for a public healthcare company with Humana insurance services and CenterWell healthcare services. Recent 8-K reports cover quarterly results, GAAP and non-GAAP earnings measures, Insurance segment benefit ratio commentary, Medicare Advantage membership assumptions, Regulation FD communications, and guidance updates.
Humana's SEC records also include proxy and annual-meeting materials covering director elections, auditor ratification, stockholder voting results, board composition, and director compensation program disclosures; board and executive transition disclosures; and capital-structure filings for registered debt offerings, including junior subordinated notes described through Form S-3 and prospectus-supplement materials.
HUMANA INC (symbol: HUM) is the issuer of record for a Form 4 filing submitted to the SEC. Nundy Shantanu reported acquisition or exercise transactions in this Form 4 filing.
HUMANA INC (HUM) reported that Chief Medical Officer Shantanu Nundy received an equity grant of 2,549 shares of Humana common stock on September 1, 2026. These are structured as restricted stock units, each representing a contingent right to one share under Humana’s 2026 Stock Incentive Plan, and are exempt under Rule 16b-3(d)(1)&(3). After this award, he holds 2,549 shares directly.
Humana Inc. (HUM) announced that senior management will meet with investors and analysts between September 1 and September 30, 2026 and plans to reaffirm FY 2026 earnings guidance. The company continues to project at least $6.52 in GAAP diluted EPS and at least $9.00 in Adjusted (non-GAAP) EPS for the year ending December 31, 2026, consistent with guidance issued on July 29, 2026.
A reconciliation shows that Adjusted EPS reflects add-backs for amortization of intangibles, put/call valuation adjustments, value creation initiatives, and impairment charges, partially offset by a cumulative net tax impact. Humana states it does not expect changes to its FY 2026 Adjusted EPS guidance, but GAAP EPS guidance may change as value creation and other strategic initiatives evolve. The company also notes it will not comment on 2027 Medicare Advantage Star Ratings until CMS releases final data in October.
HUMANA INC (HUM) reported the initial equity holdings of executive Shantanu Nundy, who serves as Chief Medical Officer. The report lists one line item for Humana Common with 0 shares beneficially owned following the reported position, indicating no direct holdings of Humana common stock at that time.
Smith Paul John reported acquisition or exercise transactions in this Form 4 filing.
Humana Inc. director Paul John Smith received an initial grant of restricted stock units under the company’s 2026 Stock Incentive Plan and annual Director Compensation Program. The award covers 544 restricted stock units, valued at $200,000, each representing a contingent right to receive one share of Humana common stock, and will be forfeited in its entirety if his board service is less than one year.
Crawford Frederick John reported acquisition or exercise transactions in this Form 4 filing.
Humana Inc. director Frederick John Crawford received an initial grant of 544 restricted stock units on August 1, 2026, under the company’s 2026 Stock Incentive Plan and annual Director Compensation Program. The award, valued at $200,000, will be forfeited if his service is less than one year. He also reports 21 shares held in managed trust accounts where he has no investment control.
Crawford Frederick John, a director of Humana Inc., reports indirect ownership of 21 shares of Humana common stock. These shares are held in managed trust accounts where he has no investment control, so they are reported as indirect holdings rather than directly owned shares.
Paul John Smith, a director of Humana Inc (HUM), filed an initial statement of beneficial ownership that reports 0.0000 shares of Humana Common held directly following the reported date. The disclosure shows one holding entry and no buy, sell, gift, or derivative transactions.
Humana Inc. expanded its Board of Directors from eleven to thirteen members and elected Paul Smith and Frederick Crawford as new independent directors, effective July 28, 2026. The board determined both qualify as independent under New York Stock Exchange director independence standards.
Smith is Chief Commercial Officer at Anthropic PBC with over 30 years leading global go-to-market strategies at major enterprise technology companies. Crawford brings more than 30 years of financial and operational experience in insurance and banking, including senior roles at Aflac, CNO Financial Group, and Lincoln Financial Group. Each will be compensated under Humana’s existing director compensation program, including grants of restricted stock units, and a press release announcing their election was issued on July 29, 2026.
Humana Inc. reported stronger second-quarter 2026 results, with revenue of $40.9 billion, up from $32.4 billion a year earlier. GAAP income before income taxes was $952 million and adjusted pretax income $1.25 billion. GAAP EPS rose to $5.73 and adjusted EPS to $7.61, both above 2025 levels.
Insurance segment revenue increased to $39.1 billion, with a benefit ratio of 91.2% and operating cost ratio of 7.1%. CenterWell revenue reached $6.8 billion and adjusted income from operations $514 million. Year-to-date operating cash flow was $3.22 billion, up from $1.60 billion, and total medical membership reached about 17.9 million, up from 14.8 million a year earlier.
Humana revised 2026 GAAP EPS guidance to at least $6.52 from at least $8.36, while affirming adjusted EPS guidance of at least $9.00 and key benefit and cost-ratio targets. The outlook reflects a year-over-year decline tied to the BY 2026 Star Ratings headwind and continued growth in Medicare Advantage and Medicaid membership.